Atlas Trials

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Clinical trial NCT05821192 · UNKNOWN

Trial details

NCT number
NCT05821192
Sponsor
Ou Bai, MD/PHD
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma
Start date
2023-03-23
Primary completion
2023-04-18
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.